Merck Sharp and Dohme

FunderResearch funding and supported work

Merck Sharp and Dohme is a funder indexed in ScholarIQ from OpenAlex. ScholarIQ records 6,864 works.

6,864

Works

IDs:OpenAlex

What are the most-cited papers on Merck Sharp and Dohme?

ScholarIQmost cited works

Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes

Michael Offin, Joseph M. Chan, Megan Tenet, Hira Rizvi, Ronglai Shen, Gregory J. Riely, Natasha Rekhtman, Yahya Daneshbod, Àlvaro Quintanal-Villalonga, Alexander Penson, Matthew D. Hellmann, Maria E. Arcila, Marc Ladanyi, Dana Pe’er, Mark G. Kris, Charles M. Rudin, Helena A. Yu

Journal of Thoracic Oncology. 2019458 CitationsOPEN ACCESS

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

Susana Banerjee, Kathleen N Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke, Charlie Gourley, Amit Oza, Antonio González-Martín, Carol Aghajanian, William H Bradley, Eileen Holmes, Elizabeth S Lowe, Paul DiSilvestro

The Lancet Oncology. 2021379 CitationsOPEN ACCESS

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Kenneth W. Mahaffey, Meg Jardine, Séverine Bompoint, Christopher P. Cannon, Bruce Neal, Hiddo J.L. Heerspink, David M. Charytan, Robert Edwards, Rajiv Agarwal, George L. Bakris, Scott Bull, George Capuano, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol A. Pollock, Tao Sun, David C. Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Norman Rosenthal, Barry M. Brenner, Vlado Perkovic, On behalf of the CREDENCE Study Investigators

Circulation. 2019291 CitationsOPEN ACCESS

Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

Eva Pros, Maria Saigí, Daniel Alameda, Gema Gómez‐Mariano, Beatriz Martínez–Delgado, Juan J. Alburquerque-Béjar, Julián Carretero, Raúl Tonda, Anna Esteve‐Codina, I. Català, Ramón Palmero, Maria Jové, Conxi Lázaro, Ana Patiño‐García, Ignacio Gil‐Bazo, Sara Verdura, Àlex Teulé, Juan Torres‐Lanzas, David Sidransky, Noemı́ Reguart, Rubén Pı́o, Óscar Juan, Ernest Nadal, Enriqueta Felip, Luis M. Montuenga, Montse Sánchez‐Céspedes

Annals of Oncology. 202056 CitationsOPEN ACCESS

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

Michael Friedländer, Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Alla Lisyanskaya, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Joyce F. Liu, Cara Mathews, Frédèric Selle, Alain Lortholary, Elizabeth Lowe, Robert Hettle, Emuella Flood, Elena Parkhomenko, Paul DiSilvestro

The Lancet Oncology. 202156 Citations